PD-Rx Pharmaceuticals, Inc. (PDRX)

PD-Rx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-0.26	-0.75	-0.1	3.03	1.86
Depreciation & Amortization	0.15	0.15	0.14	0.13	0.11
Loss (Gain) From Sale of Assets	0.01	0.01	0	-0.03	-0.01
Provision & Write-off of Bad Debts	0.16	0.16	0.35	0.27	0.25
Other Operating Activities	-0.02	0.04	-0.04	0.08	-0.94
Change in Accounts Receivable	0.93	-0.96	1.73	-0.83	-1.85
Change in Inventory	0.44	-0.59	0.2	0.82	-0.8
Change in Accounts Payable	-0.69	0.53	-0.17	-0.49	1.06
Change in Income Taxes	-0	-0	-0.29	0.24	-0.16
Change in Other Net Operating Assets	0.05	0.07	-0.03	0.03	0
Operating Cash Flow	0.77	-1.35	1.79	3.24	-0.47
Operating Cash Flow Growth	-	-	-44.71%	-	-
Capital Expenditures	-0	-0.08	-0.43	-0.55	-0.11
Sale of Property, Plant & Equipment	-	-	-	0.05	0.02
Investing Cash Flow	-0	-0.08	-0.43	-0.5	-0.09
Repurchase of Common Stock	-	-0	-0	-0.17	-
Financing Cash Flow	-	-0	-0	-0.17	-
Net Cash Flow	0.76	-1.43	1.36	2.57	-0.55
Free Cash Flow	0.76	-1.43	1.36	2.69	-0.57
Free Cash Flow Growth	-	-	-49.28%	-	-
Free Cash Flow Margin	4.16%	-7.54%	6.40%	9.35%	-2.66%
Free Cash Flow Per Share	0.47	-0.87	0.83	1.62	-0.33
Cash Income Tax Paid	0	0.01	0.31	0.7	0.14
Levered Free Cash Flow	0.73	-1.32	1.38	2.1	-0.93
Unlevered Free Cash Flow	0.73	-1.32	1.38	2.1	-0.93
Change in Working Capital	0.73	-0.96	1.44	-0.24	-1.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.